Patrick Navarro, Executive Vice President and Head of Cloud at Jefferson Frank, shares his expert advice for business leaders on surviving the COVID-19 crisis with the help of cloud technology.
Dr David Dempsey, Country Leader and General Manager, Salesforce Ireland, explores how businesses can keep the environment in mind as they start to rebuild processes after COVID-19.
Jack Perschke, Partner at Netcompany, believes that app and content design is key to capturing the public's capacity for kindness and converting it to an engaged, willing volunteer base.
The strides being made by the European Commission to achieve a digitalised society for all are explored by Assistant Editor of Open Access Government, Megan Warrender.
Vernon Hunte, Associate Director of Public Affairs at April Six, discusses how COVID-19 will change up out attitude towards artificial intelligence (AI) ethics.
Gerald Beuchelt, Chief Information Security Officer at LogMeIn, explores the key security and privacy practices which must be upheld when video conferencing.
Francesco Crivelli, PhD from CSEM Center Alpnach in Switzerland, discusses the automated 3D inspection of micro-electro-mechanical systems in this robotics & machine learning focus.
Gaurav Malhotra, Chief Technology Officer at MSC Digital, discusses the logical next steps to continue your digital journey to ensure agility, engagement, and productivity for whatever the post COVID-19 “new normal” turns out to be.
This chemistry focus delves into making nanocellulose filters for water purification with underutilised biomass, as described here by Benjamin Hsiao from Stony Brook University in the U.S.
Professor Heather Sheardown, leader of Innovation Hub C20/20, discusses their research, innovation, and development of new biomaterials-based technologies to treat a variety of disorders in the eye.
Rachel Maclean MP, Parliamentary Under Secretary of State at Department for Transport in the UK charts the UK’s transition to zero-emission vehicles, including comment on electric vehicles.
Prof Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH, shares a vision for remote decentralised clinical trials.
